Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective single-arm phase II study, and the purpose of this study is to evaluate
the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary
intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.